Bad Vilbel, January 27, 2012 –

Today, on January 27, 2012, STADA Arzneimittel AG and Grünenthal GmbH have agreed on the purchase of a branded product portfolio including the associated sales structures, also for the EU markets in Central Europe (including Poland).

STADA had originally withdrawn from this acquisition (see ad hoc release of May 12, 2011 on the start of contract negotiations as well as the ad hoc update of July 22, 2011 on the signing of the contracts, each published via DGAP), which had been pursued since May 2011, on January 1, 2012 within the scope of contractual possibilities (see ad hoc release of January 1, 2012 on the withdrawal from purchase of the branded product portfolio in Central Europe, published via DGAP).

Today, however, it was possible to successfully conclude subsequent negotiations with the seller. The purchase price for the branded product portfolio including sales structures and various pipeline products for Central Europe now amounts to a total of approx. EUR 160 million and is thus approx. EUR 48 million below the originally planned purchase price for this product package of approx. EUR 208 million. Payment of the purchase price will be made at the time of completion of the acquisition. Completion is scheduled for January 31, 2012, now that all responsible anti-trust authorities have approved the agreed transaction. In such a case the branded product portfolio for Central Europe will be consolidated in the STADA Group as of February 1, 2012.

On December 30, 2011, STADA had already successfully concluded the purchase of the branded product portfolio including the associated sales structures for numerous national markets in Eastern Europe (including Russia, Ukraine, etc.) as well as the Middle East (see ad hoc update of December 30, 2012 on the conclusion of the purchase in Eastern Europe as well as the Middle East, published via DGAP).

Together with the transaction which was agreed today, the purchase of the Grünenthal products in all originally planned markets is thus carried out. The investments made by STADA in this regard are thus reduced, as a result of the purchase price reduction agreed on today, from the original total of approx. EUR 360 million to the current total of approx. EUR 312 million.

For more information, please contact:
STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506
e-mail: communications@stada.de